Effectiveness of beta-glucan supplementation to interleukine-6, interleukine-10 and tumour necrosis factor alpha in overweight and obese subject

Phase 1

Completed

• Conditions: Inflammation; Interleukin; Tumour nacrosis factor

• Registration Number: TCTR20140604001
• Lead Sponsor: Core Chematis Co., Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-06-04
• Study Completion: 2014-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

BMI more than 23 kg m2
Agree to maintain current lifestyle e g diet and exercise during the trial

Exclusion Criteria

-Major comorbidity e g CAD cancer
-Major psychiatric disorders
-Consumption of weigh loss products or actively attempting to loss weight
-Pregnant or lactating females
-Eating disorder or laxative abuse
-Received or stopped using drug treatment on non communicable chronic diseases than 3 months
-Lost body weight 5 kg during 6 months before starting experiment
-Current or recent participant in another clinical trial 90 days

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Inflammation 2 ELISA

Secondary Outcome Measures

Name	Time	Method
General biochemical markers 2 Automated Analysis